S. Karger AG

SHERPA: Unknown

People

  1. Levine
    Levine
  2. Lowe
    Lowe
  3. Offit
    Offit
  4. Abdel-Wahab
    Abdel-Wahab
  5. Chi
    Chi
  6. Fuks
    Fuks
  7. Ladanyi
    Ladanyi
  8. Ling
    Ling
  9. Koche
    Koche
  10. Rudin
    Rudin

Groups

  1. GSK Faculty (42)
  2. Department of Medicine (30)
  3. Center for Hematologic Malignancies (24)
  4. Executive Committee, Center for Hematologic Malignancies (19)
  5. Hematologic Malignancies, Division of (19)
  6. Sloan Kettering Institute Faculty (18)
  7. Tow Center for Developmental Oncology (TCDO) (16)
  8. Human Oncology and Pathogenesis Program (14)
  9. Solid Tumor Oncology Division (13)
  10. Center for Molecular Imaging and Biotechnology (12)
Search Within
  1. "GSK Faculty"
Formats
  1. Meeting Abstract (28)
  2. Journal Article (13)
  3. Conference Paper (1)
Groups
  1. GSK Faculty (42)
  2. Department of Medicine (30)
  3. Center for Hematologic Malignancies (24)
  4. Executive Committee, Center for Hematologic Malignancies (19)
  5. Hematologic Malignancies, Division of (19)
  6. Sloan Kettering Institute Faculty (18)

More Groups

People
  1. Ross Levine (7)
  2. Marcel Van Den Brink (6)
  3. Kenneth Offit (4)
  4. Scott Lowe (4)
  5. C Ling (3)
  6. Chandra Burman (3)

More People

Years
  1. 2023 (2)
  2. 2022 (3)
  3. 2021 (2)
  4. 2020 (4)
  5. 2019 (2)
  6. 2018 (2)

More Years

Publications
  1. Oncology Research and Treatment (18)
  2. Acta Haematologica (6)
  3. Onkologie (5)
  4. Frontiers of Radiation Therapy and Oncology (3)
  5. Cytogenetics and Cell Genetics (2)
  6. Acta Cytologica (1)

More Publications

Results (42)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Quality of life and self-reported function with ripretinib in ≥4th-line therapy for patients with gastrointestinal stromal tumors: analyses from INVICTUS
    Meeting Abstract

    Bauer, S.; Heinrich, M. C.; George, S.; Zalcberg, J. R.; Gelderblom, H.; Schöffski, P.; Serrano, C.; Jones, R. L.; Attia, S.; D'Amato, G.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Neopeptide diversity and similarity to the unmutated immunopeptidome is associated with response to immune checkpoint blockade therapy
    Meeting Abstract

    Klatt, M.; Molvi, Z.; Panageas, K.; Wells, D.; Hellmann, M.; Merghoub, T.; Wolchok, J.; O'Reilly, R.; Keller, U.; Scheinberg, D.
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Durvalumab (D) + platinum-etoposide (EP) in 1L extensivestage small-cell lung cancer (ES-SCLC): Exploratory analysis of SCLC molecular subtypes in CASPIAN
    Meeting Abstract

    Xie, M.; Chugh, P.; Broadhurst, H.; Lai, Z.; Whitston, D.; Paz-Ares, L.; Gay, C.; Byers, L.; Rudin, C. M.; Stewart, R.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Resistenz auf typ II JAK2 inhibition via persistente MAPK aktivierung kann durch MEK inhibition überwunden werden
    Meeting Abstract

    Codilupi, T.; Szybinski, J.; Brkic, S.; Stivala, S.; Yang, J. L.; Wicki, A.; Ghosh, N.; Passweg, J.; Dirnhofer, S.; Levine, R. L.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • 1L durvalumab (D) + platin-etoposid (EP) beim fortgeschrittenen kleinzelligen lungenkarzinom (ES-SCLC): Explorative analyse der molekularen SCLC-subtypen in der caspian-studie
    Meeting Abstract

    Schulz, C.; Xie, M.; Chugh, P.; Broadhurst, H.; Lai, Z.; Whitston, D.; Paz-Ares, L.; Gay, C.; Byers, L.; Rudin, C. M.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Safety profile of ripretinib, including impact of alopecia, and Palmar-Plantar Erythrodysesthesia Syndrome (PPES) on patient-reported outcomes (PROs), in ≥ fourth-line advanced gastrointestinal stromal tumors (GIST): Analyses from INVICTUS
    Meeting Abstract

    Reichardt, P.; Heinrich, M.; George, S.; Zalcberg, J. R.; Bauer, S.; Gelderblom, H.; Schöffski, P.; Serrano, C.; Jones, R. L.; Attia, S.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • Clinical benefit with ripretinib as ≥ 4th line treatment in patients with advanced gastrointestinal stromal tumors (GIST): Update from the phase III INVICTUS study
    Meeting Abstract

    Bauer, S.; Heinrich, M.; George, S.; Zalcberg, J. R.; Gelderblom, H.; Schöffski, P.; Serrano, C.; Jones, R. L.; Attia, S.; D'Amato, G.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • Combined JAK2 and ERK1/2 kinase inhibition as a novel therapeutic approach in myeloproliferative neoplasms
    Meeting Abstract

    Brkic, S.; Stivala, S.; Santopolo, A.; Jungius, S.; Passweg, J. R.; Tsakiris, D.; Dirnhofer, S.; Levine, R. L.; Meyer, S. C.
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Resistance to type II JAK2 inhibition in MPN is dependent on MEK-ERK activation and is targetable
    Meeting Abstract

    Codilupi, T.; Szybinski, J.; Wicki, A.; Yang, J. L.; Ghosh, N.; Passweg, J.; Tsakiris, D.; Levine, R. L.; Koche, R.; Meyer, S. C.
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Dual genetic targeting of ERK1 and ERK2 abrogates the competitive potential of the myeloproliferative neoplasm clone
    Meeting Abstract

    Stivala, S.; Brkic, S.; Santopolo, A.; Dirnhofer, S.; Passweg, J.; Tsakiris, D.; Neel, B.; Levine, R.; Meyer, S.
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save